Oncology

Data presented at the European Society for Medical Oncology (ESMO) Congress 2025 signal a potential shift in the management of early-stage…

Treatment for advanced non-small cell lung cancer (NSCLC) with activating mutations in HER2 relies on chemo-immunotherapy in the…

Dr. Joshua Sabari explores recent advances in the treatment of HER2-mutant non-small cell lung cancer, including a newly FDA-approved option…

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized endocrine therapies…

Patients with cancer often have a compromised immune system, which places them at an increased risk of infection that can extend beyond…

Mutations in HER2, also known as ERBB2, represent a distinct molecular subset of NSCLC, occurring in approximately 2–4% of cases, and are…

EpNECs are considered rare and are often associated with a poor prognosis, with up to 85% of patients presenting with advanced…